Long-term therapeutic success with multimodal therapy in aggressive prolactinoma
Endocrinol Diabetes Nutr (Engl Ed). 2019 Aug-Sep;66(7):464-466.
doi: 10.1016/j.endinu.2019.01.002.
Epub 2019 Feb 21.
[Article in
English,
Spanish]
Affiliations
- 1 Department of Endocrinology, Hospital Universitario Ramón y Cajal y Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. Electronic address: piglo65@gmail.com.
- 2 Department of Neurosurgery, Hospital Ramón y Cajal, Madrid, Spain.
- 3 Department of Pathology, Hospital Ramón y Cajal, Madrid, Spain.
- 4 Department of Endocrinology, Hospital Universitario Ramón y Cajal y Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
No abstract available
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cabergoline / administration & dosage
-
Combined Modality Therapy
-
Disease Progression
-
Female
-
Humans
-
Hydrocortisone / administration & dosage
-
Hypophysectomy*
-
Magnetic Resonance Imaging
-
Middle Aged
-
Neoplasm Invasiveness
-
Neoplasm Recurrence, Local / diagnostic imaging
-
Neoplasm Recurrence, Local / therapy
-
Peptides, Cyclic / administration & dosage
-
Pituitary Neoplasms / diagnostic imaging
-
Pituitary Neoplasms / pathology
-
Pituitary Neoplasms / therapy*
-
Prolactinoma / diagnostic imaging
-
Prolactinoma / pathology
-
Prolactinoma / therapy*
-
Radiosurgery*
-
Somatostatin / administration & dosage
-
Somatostatin / analogs & derivatives
-
Temozolomide / administration & dosage
-
Thyroxine / administration & dosage
-
Treatment Outcome
Substances
-
Peptides, Cyclic
-
lanreotide
-
Somatostatin
-
Cabergoline
-
Thyroxine
-
Hydrocortisone
-
Temozolomide